Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11979603 | 0.91 | HTT (0.48) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL29008276 | 0.80 | HTT (0.47) | HTTTP53TSHRLMNAFABP4 | |
| Eprodisate SCHEMBL6114464 | 0.76 | NFKB1 (0.56) | HTTAPPALDH1A1TBXAS1EGLN3 | |
| SCHEMBL25091028 | 0.76 | HTT (0.50) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL4599902 | 0.73 | TBXAS1 (0.59) | L3MBTL1TBXAS1EGLN3 | |
| SCHEMBL1006550 | 0.72 | HTT (0.55) | HTTTP53TSHRLMNAFABP4 | |
| SCHEMBL23839355 | 0.72 | HTT (0.37) | HTTTP53TSHRLMNAALDH1A1 | |
| SCHEMBL27532488 | 0.72 | — | — | |
| SCHEMBL1275585 | 0.72 | — | — | |
| SCHEMBL12929091 | 0.71 | TBXAS1 (0.62) | TBXAS1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051248-B2 | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2015-06-09 | — | — | US | disclosed |
| US-9051248-B2 | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2015-06-09 | — | — | US | disclosed |
| US-20120208850-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | BELLUS HEALTH INC. (CA) | 2012-08-16 | — | — | US | disclosed |
| US-20120208850-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | BELLUS HEALTH INC. (CA) | 2012-08-16 | — | — | US | disclosed |
| WO-2011017800-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPAN ED ISULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208850-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | SGMS1, GSS, HPGDS | HTT 56/4885TP53 775/4885TSHR 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.